COMPASS Pathways plc (CMPS) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-05-13

Key Insights

COMPASS Pathways reported Q1 2026 financial results via press release on May 13, 2026, though the actual financial figures and performance details are not included in this 8-K filing itself.
The filing is a routine quarterly earnings announcement with minimal disclosure, as the substantive financial information is contained in the attached press release (Exhibit 99.1) rather than in the 8-K body.
Teri Loxam, the Chief Financial Officer, signed the filing, indicating proper authorization and standard corporate governance procedures are being followed.

Want the newest filings?

This analysis covers the filing from 2026-05-13. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-03-24

COMPASS Pathways plc reported its financial results for the year ended December 31, 2025, indicating the company's continued progress and development of its pipeline of psychedelic-based therapies.
The filing does not mention any major changes in leadership or material business agreements, suggesting the company's operations are progressing as expected.
Investors should closely monitor the company's progress in advancing its clinical trials and regulatory approvals, as this will be crucial for the long-term success of the business.

Filed: 2026-02-19

COMPASS Pathways plc announced a $150 million public offering of American Depositary Shares (ADSs) and pre-funded warrants to purchase ADSs, which could provide additional funding to support the company's drug development efforts.
The offering includes an over-allotment option for the underwriters to purchase up to an additional 2.8 million ADSs, potentially increasing the total gross proceeds.
The pre-funded warrants have an exercise price of $0.0001 per ADS and include a beneficial ownership limitation, which could impact future share ownership and control.

Filed: 2026-02-17

COMPASS Pathways reported positive results from the Phase 3 COMP006 trial, with the 25 mg dose of COMP360 demonstrating a highly statistically significant reduction in symptom severity for treatment-resistant depression compared to the 1 mg dose.
The data from both the COMP005 and COMP006 trials suggest that COMP360 is generally well-tolerated, with most treatment-emergent adverse events being mild or moderate and resolving within 24 hours.
COMPASS Pathways plans to meet with the FDA to discuss a rolling submission and review for COMP360, indicating potential progress towards regulatory approval.

Filed: 2026-01-07

COMPASS Pathways has secured a $150 million loan facility from Hercules Capital, providing additional funding to support its clinical and commercial development efforts.
The loan agreement includes multiple tranches with milestone-based funding, allowing COMPASS to access capital as it achieves certain clinical and regulatory milestones.
The loan agreement includes customary terms and covenants, including interest-only payments until 2029 and a financial covenant requiring the company to maintain a minimum cash balance.

Other reports for COMPASS Pathways plc

Quarterly Report Insider Trading Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.